References
1. Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics
Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and
Tacrolimus Dosing. Clin Pharmacol Ther . 2015;98(1):19-24.
2. Brunet M, van Gelder T, Åsberg A, et al. Therapeutic Drug Monitoring
of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther
Drug Monit . 2019;41(3):261-307.
3. Schumacher L, Leino AD, Park JM. Tacrolimus intrapatient variability
in solid organ transplantation: A multiorgan perspective.Pharmacotherapy . 2021;41(1):103-18.
4. Mendoza Rojas A, Hesselink DA, van Besouw NM, et al. Impact of low
tacrolimus exposure and high tacrolimus intra-patient variability on the
development of de novo anti-HLA donor-specific antibodies in kidney
transplant recipients. Expert Rev Clin Immunol .
2019;15(12):1323-31.
5. Leino AD, King EC, Jiang W, et al. Assessment of tacrolimus
intrapatient variability in stable adherent transplant recipients:
Establishing baseline values. Am J Transplant .
2019;19(5):1410-20.
6. Whalen HR, Glen JA, Harkins V, et al. High Intrapatient Tacrolimus
Variability Is Associated With Worse Outcomes in Renal Transplantation
Using a Low-Dose Tacrolimus Immunosuppressive Regime.Transplantation . 2017;101(2):430-6.
7. Gallagher HM, Sarwar G, Tse T, et al. Erratic tacrolimus exposure,
assessed using the standard deviation of trough blood levels, predicts
chronic lung allograft dysfunction and survival. J Heart Lung
Transplant . 2015;34(11):1442-8.
8. Kao CC, Segraves J, Parulekar AD. Tacrolimus monitoring parameters
are not associated with acute cellular rejection following lung
transplantation. Eur J Clin Pharmacol . 2021;77(1):63-9.
9. Ensor CR, Iasella CJ, Harrigan KM, et al. Increasing tacrolimus
time-in-therapeutic range is associated with superior one-year outcomes
in lung transplant recipients. Am J Transplant .
2018;18(6):1527-33.
10. Garrity ER, Jr., Hertz MI, Trulock EP, et al. Suggested guidelines
for the use of tacrolimus in lung-transplant recipients. J Heart
Lung Transplant . 1999;18(3):175-6.
11. Gray AL, Mulvihill MS, Hartwig MG. Lung transplantation at Duke.J Thorac Dis . 2016;8(3):E185-96.
12. Neurohr C, Huppmann P, Zimmermann G, et al. Tacrolimus and
mycophenolate mofetil as first line immunosuppression after lung
transplantation. Transpl Int . 2009;22(6):635-43.
13. Du WW, Wang XX, Zhang D, et al. Retrospective analysis on incidence
and risk factors of early onset acute kidney injury after lung
transplantation and its association with mortality. Ren Fail .
2021;43(1):535-42.
14. Sikma MA, Hunault CC, van de Graaf EA, et al. High tacrolimus blood
concentrations early after lung transplantation and the risk of kidney
injury. Eur J Clin Pharmacol . 2017;73(5):573-80.
15. Ryu JH, Choi S, Lee HJ, et al. Low early posttransplant serum
tacrolimus levels are associated with poor patient survival in lung
transplant patients. Ann Thorac Med . 2019;14(3):186-91.
16. Stefanović NZ, Veličković-Radovanović RM, Danković KS, et al.
Combined Effect of Inter- and Intrapatient Variability in Tacrolimus
Exposure on Graft Impairment Within a 3-Year Period Following Kidney
Transplantation: A Single-Center Experience. Eur J Drug Metab
Pharmacokinet . 2020;45(6):749-60.
17. Park Y, Lee H, Eum SH, et al. Combined impact of the inter and
intra-patient variability of tacrolimus blood level on allograft
outcomes in kidney transplantation. Front Immunol .
2022;13:1037566.
18. Seibert SR, Schladt DP, Wu B, et al. Tacrolimus trough and dose
intra-patient variability and CYP3A5 genotype: Effects on acute
rejection and graft failure in European American and African American
kidney transplant recipients. Clin Transplant .
2018;32(12):e13424.
19. Baghai Arassi M, Gauche L, Schmidt J, et al. Association of
intraindividual tacrolimus variability with de novo donor-specific HLA
antibody development and allograft rejection in pediatric kidney
transplant recipients with low immunological risk. Pediatr
Nephrol . 2022;37(10):2503-14.
20. Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft
dysfunction: Definition, diagnostic criteria, and approaches to
treatment-A consensus report from the Pulmonary Council of the ISHLT.J Heart Lung Transplant . 2019;38(5):493-503.
21. Darley DR, Carlos L, Hennig S, et al. Tacrolimus exposure early
after lung transplantation and exploratory associations with acute
cellular rejection. Eur J Clin Pharmacol . 2019;75(7):879-88.
22. Miano TA, Flesch JD, Feng R, et al. Early Tacrolimus Concentrations
After Lung Transplant Are Predicted by Combined Clinical and Genetic
Factors and Associated With Acute Kidney Injury. Clin Pharmacol
Ther . 2020;107(2):462-70.
23. Destere A, Premaud A, Monchaud C, et al. Longitudinal Exposure to
Tacrolimus and New-Onset Diabetes Mellitus in Renal Transplant Patients.Ther Drug Monit . 2023;45(1):102-9.
24. Gonzales HM, McGillicuddy JW, Rohan V, et al. A comprehensive review
of the impact of tacrolimus intrapatient variability on clinical
outcomes in kidney transplantation. Am J Transplant .
2020;20(8):1969-83.
25. Coste G, Lemaitre F. The Role of Intra-Patient Variability of
Tacrolimus Drug Concentrations in Solid Organ Transplantation: A Focus
on Liver, Heart, Lung and Pancreas. Pharmaceutics . 2022;14(2).
26. Oetting WS, Schladt DP, Guan W, et al. Genomewide Association Study
of Tacrolimus Concentrations in African American Kidney Transplant
Recipients Identifies Multiple CYP3A5 Alleles. Am J Transplant .
2016;16(2):574-82.
27. Ro H, Min SI, Yang J, et al. Impact of tacrolimus intraindividual
variability and CYP3A5 genetic polymorphism on acute rejection in kidney
transplantation. Ther Drug Monit . 2012;34(6):680-5.
28. Nuchjumroon A, Vadcharavivad S, Singhan W, et al. Comparison of
Tacrolimus Intra-Patient Variability during 6-12 Months after Kidney
Transplantation between CYP3A5 Expressers and Nonexpressers. J
Clin Med . 2022;11(21).